Black Diamond Therapeutics, Inc. Common Stock BDTX
Analyst Ratings
- Consensus
- Buy — 4 Buy · 1 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $11.00 (+441.9% upside)
Key Stats
- Today's Range
- $1.97 – $2.04
- 50-Day Range
- $1.62 – $2.32
- 52-Week Range
- $1.60 – $4.94
- Volume
- 514K shs
- Average Volume
- 569K shs
- Market Cap
- $113.76 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.18
- Price / Sales
- —
Short Interest
- Short Interest
- 2.27%
- Days to Cover
- 3.94
Financials (TTM)
- Revenue
- —
- Net Income
- $-42,555,000
- Net Margin
- —
- Return on Equity
- -44.29%
- Debt-to-Equity
- —
About Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Related Stocks
Compare head-to-head: BDTX vs AMGN·BDTX vs MRNA·BDTX vs HALO·BDTX vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.